Solu Therapeutics key facts
as of Oct 2026- Developer of bifunctional small-molecule therapeutics designed to eliminate disease-driving cells.
- Solu Therapeutics is valued at approximately $104.0M as of Oct 2026 (last reported valuation).
- It has raised $72.0M; the latest was Early Stage VC ($41.0M) in Apr 2025.
- Notable investors include Alexandria Venture Investments, DCVC Bio, Astellas Venture Management, Biovision Ventures, Eli Lilly — 11 tracked in total.
- Status: Privately Held (backing).
Solu Therapeutics's last reported valuation, Apr 2025. Nothing priced has surfaced since.
- ·The complete investor list: 11 names
- ·Watch Solu Therapeutics: the Monday email on marks, rounds and moves
Solu Therapeutics funding rounds
No funding rounds for Solu Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Solu Therapeutics
11+Solu Therapeutics valuation
Solu Therapeutics's last reported valuation was $104 million in Apr 2025. No priced round, secondary trade or fund mark has surfaced since.
Solu Therapeutics investors
11 investors are on record for Solu Therapeutics, including Alexandria Venture Investments, DCVC Bio, Astellas Venture Management and Biovision Ventures.
About Solu Therapeutics
Developer of bifunctional small-molecule therapeutics designed to eliminate disease-driving cells. The company's platform combines selective small-molecule binders with proprietary antibodies and provides oncology therapeutics, eliminating cells that drive inflammatory and autoimmune diseases, enabling medical professionals to improve specificity and efficacy through deep binding pockets and reduce safety risks.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2022
- Employees
- 7
- Website
- solutherapeutics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.